| answer text |
<p>The Government wants patients to be able to benefit from access to effective new
treatments as quickly as possible.</p><p>Through its technology appraisal and highly
specialised technologies guidance, the National Institute for Health and Care Excellence
(NICE) makes authoritative, evidence-based recommendations on whether medicines and
other treatments represent a clinically and cost effective use of National Health
Service resources. NHS organisations are legally required to make funding available
for NICE recommended treatments, usually within three months of final guidance.</p><p>Wherever
possible, NICE currently aims to publish recommendations on new drugs as soon as possible
after licensing, with draft guidance on cancer drugs published in advance of licensing.
The 2019 Voluntary Scheme for Branded Medicines Pricing and Access includes a commitment
to faster NICE assessments of new medicines, with timelines for non-cancer drugs to
match those for cancer drugs, subject to the evidence base for the product being sufficiently
developed.</p>
|
|
